CLPT, a company in the healthcare industry, has been on the rise despite a recent earnings miss. The last earnings report on December 31st showed a lower earnings per share than expected, but the company has since shown promising technical indicators.
With a P/B Ratio of 6.231 and a P/E Ratio of 0.000, CLPT is on par with comparable stocks in the industry. The PEG Ratio, which measures projected growth, is also within normal values. Although the company does not offer a dividend, the P/S Ratio is in line with the average among similar stocks.
One standout factor for CLPT is its recent upward trend. On April 6th, 2023, the stock moved above its 50-day moving average, indicating a change from a downward trend to an upward trend. In fact, A.I.dvisor has found that in 37 of 41 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are currently at 90%.
Interestingly, A.I.dvisor also suggests a loose correlation between CLPT and another healthcare stock, OPK. These tickers have moved in lockstep 51% of the time over the past year, indicating a potential price increase for OPK if CLPT continues its upward trend.
While the recent earnings miss may have initially caused concern for investors, the positive technical indicators and upward trend suggest that CLPT is still a promising investment opportunity. As always, it is important to do your own research and consider all factors before making any investment decisions.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CLPT advanced for three days, in of 277 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on July 02, 2025. You may want to consider a long position or call options on CLPT as a result. In of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 60 cases where CLPT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for CLPT turned negative on July 02, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 59 similar instances when the indicator turned negative. In of the 59 cases the stock turned lower in the days that followed. This puts the odds of success at .
CLPT moved below its 50-day moving average on June 12, 2025 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLPT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
CLPT broke above its upper Bollinger Band on June 06, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CLPT entered a downward trend on June 18, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CLPT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.576) is normal, around the industry mean (24.307). P/E Ratio (0.000) is within average values for comparable stocks, (77.706). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (6.911) is also within normal values, averaging (42.612).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLPT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a company, which engages in the development and commercialization of innovative platforms for performing minimally invasive surgical procedures in the brain and heart.
Industry MedicalSpecialties